NEXT-GENERATION AI
More about us
ABOUT US
In MNM Bioscience, we combine next-generation AI with the most advanced genomic approaches (Whole-genome and Multiomics data) to save the lives of cancer patients through predictive modeling and drug target identification.
For that purpose, we developed CARTHERai and TARGET DISCOVERY PLATFORM.
TECHNOLOGY
We harvest the power of whole-genome and MultiOmics data through proprietary AI solutions for
therapy response predictions and drug target identification
CDx DEVELOPMENT PIPELINE
Portfolio of predictive and prognostic models ready for licensing.
We invite investors and biopharma companies to collaborative partnerships in CDx development.
OUR PUBLICATIONS
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
The First Report of Biallelic Missense Mutations in the SFRP4 Gene Causing Pyle Disease in Two Siblings
A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection
Pawel Zawadzki,
Co-founder and CEO
The idea for MutationsNoMore (MNM) was born while I was at Oxford University, where I understood that a new “dictionary” for interpreting a tumor’s mutation language is needed.
Over the past three years, we have built technology translating different mutation types; from single point mutations, structural changes to patterns of mutations into biological insights.
Unfortunately, we have discovered that there is no appropriate AI technology to process this new type of data, so we have built a new AI framework – our most valuable asset.
I am proud that MNM’s newly discovered insights are already being validated in clinics in the form of algorithms predicting response to cancer drugs, and new drug targets we discovered are ready for validation.
